As part of strategic restructuring, Proteostatis is laying off 46 percent of its R&D workforce, or 13 positions. Source: BioSpace

The company submitted 15 abstracts to be presented at the upcoming ASH Conference. Source: BioSpace

ALZ’s researchers continue to see hope in Biogen's aducanumab. Source: BioSpace

The Crestwood, KY-based company plans to raise $150M by offering 10.7 million shares at a price range of $13 to $15. Source: BioSpace

Investors and analysts are wondering if the company should buy a biotech to bolster its pipeline and bottom line. Source: BioSpace

Dupilumab added to standard therapies significantly reduced the use of maintenance oral corticosteroids (OCS) by 70% on average. Source: BioSpace

Shares of Voyager have fallen more than 12 percent in premarket trading after Sanofi Genzyme walked away from its $845M gene therapy treatment for Parkinson’s disease. Source: BioSpace

Based on feedback from the FDA, Stemline remains on track to begin submission of its BLA in the 4Q17-1Q18 timeframe. Source: BioSpace

Astra and Incyte are pushing forward on the development of immunotherapy combination treatments. Source: BioSpace

Amgen and Kirin have decided to dissolve their joint venture, Kirin-Amgen. Source: BioSpace